Chromocell Therapeutics Past Earnings Performance
Past criteria checks 0/6
Chromocell Therapeutics's earnings have been declining at an average annual rate of -80.5%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 245% per year.
Key information
-80.5%
Earnings growth rate
-2.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -245.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Chromocell Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 4 | 0 |
| 30 Sep 23 | 0 | -5 | 4 | 0 |
| 30 Jun 23 | 0 | -4 | 3 | 0 |
| 31 Mar 23 | 0 | -3 | 2 | 0 |
| 31 Dec 22 | 0 | -2 | 2 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
Quality Earnings: CHRO is currently unprofitable.
Growing Profit Margin: CHRO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CHRO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CHRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CHRO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.